An average Q3 report for Photocure today giving some selling action, painting up the framework for a nice inverted head & shoulders formation within the long uptrend of the stock.
Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan
Agreement Expands Photocure’s Hexvix®/Cysview® Franchise Footprint to over 30 Countries
Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, ...
100 NOK the last major resistance in the chart.
Ready to break out from Triangle formation.
Nice EMA 20 / 100 Bounce
Strong Analyst BUY consensus from DNB Markets, ABG, Norne etc.
So I can be quick on Photocure.
We are in a nice long uptrend, which is currently hitting resistance, forming an ascending triangle.
The only sure strategy here is to wait for a break and retest of this triangle.
ABG Sundal Collier: Photocure - Q3: a solid stepping stone towards expansion
Q3 results due 10 November US recovery and EU commercialisation in the spotlight Tweaking near term ests. – DCF TP up to NOK 130 (125)
The whole stock market is experiencing the same type of "crack" as it did back in Feb/March, now being fueled by a Covid second wave and uncertainty around the US elections. Photocure's RSI is approaching its year low levels in March. The down period in March lasted for about 1 month. The length of this down period will be more uncertain depending on the outcome...
The Photocure share price has been increasing steadily even in the face of short sellers thas has been adding to their positions in Photocure stock for three weeks straight.
With the stock now trading above the last top, longs will be hoping to see a short squeeze effect in the the price development.
Recent 50SMA / 200SMA golden cross.
Top 20 ownership...
Recent oversubscribed equity offerings done at 76 and 65,5 NOK after repurchasing global Hexvix ownership from Ipsen now securely in the money.
Recent newsflow:
13.08.2020 Photocure appoints Genotests as exclusive partner for Hexvix in Chile
08.07.2020 Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for...
Largest owner in Photocure OSL:PHO apparently being forced to dump the whole position in the stock in the course of a few days, giving the stock extra momentum to the downside.
Updated list of shareholders show influx of US actors.
twitter.com
Patent covering the use of Blue Light Cystoscopy (BLC®) with Hexvix as neoadjuvant* therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy.
Early stage study results have shown an antitumor effect and induced systemic immune effects of hexaminolevulinate (HAL) and blue light in an orthotopic model of rat bladder cancer....
Recent news by OSL:PHO :
Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
photocure.com
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
photocure.com
Further...
Photocure OSL:PHO presented Q3 numbers with top line numbers just a hint weaker than consensus, but with the strongest quarterly growth rate in deployed cystoscopes ever noted.
The stock is currently trading above earlier support, and a move through NOK 60 could trigger a strong BUY signal.
Q3 Report:
photocure.com
Q3 webcast in english with CEO Daniel...
